Deals in Depth: January 2011
Eli Lilly and Boehringer Ingelheim signed a risk-sharing deal worth over $2 billion to co-develop several diabetes candidates. To gain access to viral cancer vaccines, Amgen paid $425 million up front for BioVex, which could get another $575 million in regulatory and sales earn-outs. Three fundraises (from Symphogen, Nektar, and Pharmasset) that brought in over $100 million each contributed significantly to the $1.1 billion in biopharma financing. For the first time in six months, no device company completed a public offering in January - money invested in this industry totaled only $188 million, a 52% decrease from December's $391 million.
You may also be interested in...
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
Samsung Bioepis has announced that its SB17 proposed biosimilar ustekinumab rival to Janssen’s $7.7bn Stelara brand has moved into Phase I trials.